ADME-Tox expert, with a top-notch knowledge in drug metabolism, drug-drug-interactions & quantitative bioanalysis. From highly tailored studies to high-throughput screenings.
Admescope Ltd is a Finnish ADME-Tox contract research company founded in 2011. Straight from the beginning, Admescope’s growth has been exponential and today Admescope is managed by a team with a strong background in CRO business. Since 2020, Admescope has been a part of Symeres, with the ability to provide medicinal chemistry and integrated drug discovery & development services through the Symeres organization.
The team consists of chemists, biochemists, pharmacologists and technicians, all with long experience and strong expertise in ADME-studies. Admescope serves customers in >30 different countries on five continents, having planned and conducted a high number of ADME-related studies to biotech and big pharma companies.
Our continuous service development and ability to adapt customers’ in-house processes has a lot to do with our outstanding customer satisfaction rates. Performing beyond our customers’ needs and expectations is important to us therefore we invest a lot of time, money and effort into R&D.
The aim of our R&D activities is to strengthen our position in the market and further improve our expertise and skill set, as well as being able provide even more innovative and efficient ways to conduct studies and produce top quality data for our customers.